Zu-Chian Chiang | Biochemistry | Best Researcher Award | 13347

Posted on by sciencefather

Dr. Zu-Chian Chiang | Biochemistry | Best Researcher Award 

Dr. Zu-Chian Chiang, Fujian Normal University, China

Dr. Zu-Chian Chiang is a postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, China, with a rich background in materials and chemical engineering. His research contributions span antibody-drug conjugates (ADCs), functional peptide synthesis, biomaterials for regenerative medicine, and aptamer-based cancer therapy. His work has geographic impact across Taiwan and Mainland China, contributing to translational medicine and oncology through collaborative efforts with prestigious institutions like Academia Sinica and National Taiwan University. His applied research in ADCs and biomaterial scaffolds directly supports cancer treatment innovations. Notable projects include the development of CD47-targeting ADCs for non-small cell lung cancer, and thalidomide-PD1 combinations for enhanced immunotherapy. His publications in Frontiers in Oncology, PLOS ONE, and Current Pharmaceutical Biotechnology highlight his influence in drug delivery and cancer therapeutics. In the vector control domain, his scaffold research contributes to potential localized drug delivery systems. Dr. Chiang has received awards such as the Science and Technology Commissioner honor from Quanzhou and the Biotech Elite Training Award. His achievements exemplify impactful biomedical research with real-world therapeutic implications.

Profile

Scopus

🌱 Early Academic Pursuits

Dr. Zu-Chian Chiang embarked on his scientific journey with a passion for chemistry and materials science. He earned his Master’s Degree in Chemistry from Tunghai University, Taiwan (2005–2007), under the guidance of Prof. Feng-Di Lung. Building on this solid foundation, he pursued his Ph.D. in Materials and Chemical Engineering at National United University, Taiwan (2008–2014). During his doctoral studies, he was mentored by Prof. An-Chong Chao and co-advised by Dr. Guo-Chung Dong, focusing on biomaterials and nanomedicine.

Even as a student, Dr. Chiang demonstrated exceptional academic capabilities, earning scholarships and recognition for his innovative research. His academic training laid the groundwork for his future contributions in biomedical engineering and cancer therapeutics.

🧪 Professional Endeavors

Dr. Chiang has held several prestigious postdoctoral positions. His professional journey reflects a commitment to interdisciplinary collaboration and translational research:

  • Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University (2019–Present), working under Prof. Qi Chen.

  • Postdoctoral Fellow at the Institute of Biological Chemistry, Academia Sinica, Taiwan (2016–2019), contributing to the Taiwan Protein Project (TPP) and the Technical Support Platform Spindle Project (TSPA).

  • Postdoctoral Fellow at the Clinical Trial Center, National Taiwan University Hospital (2015–2016), supported by Taiwan’s prestigious Biotech Elite Training Program.

Throughout these roles, Dr. Chiang has engaged in cutting-edge biomedical research with direct implications for drug development and clinical applications.

🔬 Contributions and Research Focus

Dr. Chiang’s research centers on innovative therapeutic materials and drug delivery systems, particularly in cancer therapy. His core interests include:

  • Antibody-Drug Conjugates (ADCs): Targeted cancer therapies such as HER2-positive and CD47-specific ADCs.

  • Functional Peptide Synthesis for bone tissue engineering and cancer inhibition.

  • Bio-Micro-Macro Molecular Materials for regenerative medicine.

  • Aptamer Development as modulators in therapeutic settings.

Notable publications include research on CD47-targeting ADCs (Frontiers in Oncology, 2022) and HER2-positive ADCs (PLOS ONE, 2020). His work on dexamethasone-immobilized chitosan scaffolds and chitosan-caffeic acid hybrids also provides valuable insights into localized drug delivery and tissue engineering.

🏆 Accolades and Recognition

Dr. Chiang’s dedication has been acknowledged through numerous awards:

  • 🥇 Science and Technology Commissioner, Quanzhou, Fujian Province (2020)

  • 🥇 Biotech Elite Training Award, National Taiwan University & Ministry of Science and Technology (2016)

  • 🥇 Chung Hwa Rotary Doctoral Program Award, Taiwan (2012)

  • 🥇 Outstanding Doctoral Scholarship, National United University (2010)

  • 🥇 Master’s Program Scholarship, Hunan Fellow Association of Taiwan (2007)

  • 🥇 Rotary Leadership Award, Miaoli Southeastern Xindong Satellite Rotary Club (2017)

These accolades affirm his position as a respected figure in the fields of biomedical chemistry and translational medicine.

🌍 Impact and Influence

Dr. Chiang’s work has made a geographic impact spanning Taiwan and Mainland China. His collaborative research in academia and clinical centers bridges the gap between laboratory research and therapeutic application. He actively contributes as a peer reviewer for the International Journal of Biological Macromolecules, influencing scientific standards and publication quality globally.

He is also engaged in community service through leadership in Rotary International, fostering science-driven community development and education.

🌟 Legacy and Future Contributions

Dr. Chiang’s legacy is being built on the foundation of scientific excellence, mentorship, and translational impact. His research not only pushes the boundaries of biomedical engineering but also aims to enhance the effectiveness of cancer treatments in clinical practice. With a commitment to developing next-generation targeted therapies and biomaterial scaffolds, Dr. Chiang is poised to shape the future of personalized medicine and regenerative technologies.

Looking ahead, he aims to establish interdisciplinary collaborations and contribute to global health initiatives, making life-saving therapies more effective and accessible.

Publication Top Notes

Development of Novel CD47-Specifific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. 

Author: Z.C., Chiang, Zu Chian, S., Fang, Shubin, Y., Shen, Yangkun, … J., Lin, Jizhen, Q., Chen, Qi

Journal: Frontiers in Oncology,

Year: 2022

Preparation and characterization of dexamethasone-immobilized chitosan scaffold

Author: Z.C., Chiang, Zu Chian, S., Yu, Shuhuei, A., Chao, Anchong, G.C., Dong, Guo Chung

Journal: Journal of Bioscience and Bioengineering, 

Year: 2012

 

Wenjian Mao | Health Sciences | Best Researcher Award | 13235

Posted on by sciencefather

Mr. Wenjian Mao | Health Sciences | Best Researcher Award

Mr. Wenjian Mao, Jinling Hospital, Nanjing University, China

Mr. Wenjian Mao is a postdoctoral researcher at the Department of Critical Care Medicine, Nanjing University, China. He holds a Medical Doctor degree from Nanjing Medical University and specializes in the diagnosis and treatment of acute pancreatitis, with a focus on clinical and experimental research. His academic contributions include multiple publications in prestigious journals, covering topics such as infected pancreatic necrosis, systemic anticoagulation, immune dysfunction, and kidney complications in acute pancreatitis. He is affiliated with Jinling Hospital, Nanjing University.

Profile

Orcid

Scopus

Early Academic Pursuits 🎓

Wenjian Mao embarked on his academic journey in medicine with a strong foundation at Guangzhou Medical University, where he earned his Bachelor of Medicine degree between 2011 and 2016. During this time, he developed a keen interest in medical sciences, particularly in the field of critical care and acute conditions. Building upon this foundation, he pursued a Master of Medicine at Southern Medical University from 2016 to 2019. His academic pursuits were characterized by a rigorous exploration of clinical medicine, setting the stage for his specialization in acute pancreatitis. His passion for advancing medical knowledge and patient care led him to enroll in the Medical Doctor program at Nanjing Medical University, where he further honed his expertise from 2019 to 2022. This progression through highly regarded medical institutions equipped him with a strong clinical and research background that would later define his professional contributions.

Professional Endeavors 🏥

Following his extensive education, Wenjian Mao took on the role of a postdoctoral researcher at Nanjing University’s Department of Critical Care Medicine. His professional experience is deeply rooted in the diagnosis and treatment of acute pancreatitis, a condition that presents significant challenges in critical care settings. His clinical practice at Jinling Hospital, affiliated with Nanjing University, has been instrumental in shaping his understanding of the disease’s complexities. He is actively engaged in both clinical and experimental research, striving to develop innovative approaches to the management and treatment of acute pancreatitis. His expertise encompasses patient assessment, therapeutic interventions, and longitudinal studies aimed at improving clinical outcomes. His work not only benefits individual patients but also contributes to the broader medical community’s understanding of acute pancreatitis management.

Contributions and Research Focus 📚

Wenjian Mao’s research is primarily focused on acute pancreatitis, with an emphasis on early detection, management, and patient outcomes. His scholarly contributions include a range of peer-reviewed publications that address critical aspects of pancreatitis treatment. His study on the prediction of infected pancreatic necrosis using the modified pancreatitis activity scoring system provides valuable insights into early intervention strategies. Additionally, his research on systemic anticoagulation in acute necrotizing pancreatitis patients has shed light on reducing hospital readmissions, improving patient recovery, and minimizing complications.

Other notable studies include his exploration of immune function in severe pancreatitis cases, where he was involved in a multicenter, double-blind, randomized controlled trial focusing on immune enhancement therapy. His work in identifying key biomarkers, such as mean absolute lymphocyte count as a predictor of infected pancreatic necrosis, further underscores his commitment to advancing diagnostic precision in the field. Moreover, his investigation into autoantibodies as independent risk factors for hypertriglyceridemia-induced pancreatitis recurrence highlights his innovative approach to understanding disease mechanisms. These contributions collectively enhance the medical community’s ability to diagnose, treat, and manage acute pancreatitis more effectively.

Accolades and Recognition 🏆

As a result of his groundbreaking work, Wenjian Mao has gained recognition in the medical research community. His studies have been published in reputable journals such as United European Gastroenterology Journal, Hepatobiliary Pancreatic Diseases International, Intensive Care Medicine, and the Journal of Clinical Lipidology. His findings have contributed to a growing body of literature that informs best practices in critical care and gastroenterology. Additionally, his collaborative efforts with other leading researchers have led to impactful studies on sepsis-related immune dysfunction and major adverse kidney events in pancreatitis patients. These accomplishments reflect his dedication to scientific excellence and his ongoing commitment to improving patient care.

Publication Top Notes

Triglyceride lowering in patients with different severities of hypertriglyceridaemia-associated acute pancreatitis: secondary analysis of a multicentre, prospective cohort study

Contributors: Xiang Luo; Xiaoling Li; Xiaoyan Lai; Wenjian Mao; Lu Ke; Lingyan Fu; Lin Gao; Yaolu Liu
Journal: BMJ Open Gastroenterology
Year: 2025

Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial

Contributors: Xiaofei Huang; Wenjian Mao; Xingxing Hu; Fengxia Qin; Hui Zhao; Aiping Zhang; Xinyu Wang; Christian Stoppe; Dandan Zhou; Lu Ke et al.
Journal: Gut and Liver
Year: 2024

The Diagnosis and Treatment of Local Complications of Acute Necrotizing Pancreatitis in China: A National Survey

Contributors: Xiaowu Dong; Wenjian Mao; Lu Ke; Lin Gao; Jing Zhou; Bo Ye; Gang Li; Anthony Phillips; Zhihui Tong; John Windsor et al.
Journal: Gastroenterology Research and Practice
Year: 2021